Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of MK-2010 plus sacituzumab tirumotecan in advanced solid tumors
MOH_2026-10-08_017072Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-299 and sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), endometrial cancer (EC), Cervical Cancer (CC) and 1 more (5 arms), sponsored by Merck & Co. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
LM-299sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)endometrial cancer (EC)Cervical Cancer (CC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2026-10-08_017072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-08_017072.